Role of immunotherapy in chondrosarcoma: A case report and review of the literature.

Autor:	Cohen-Nowak AJ; McGaw Medical Center of Northwestern University, Chicago, IL, USA., Dressler DB; McGaw Medical Center of Northwestern University, Chicago, IL, USA., Rock A; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Mojica K; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Woo D; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Zuckerman LM; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Chow W; University of California, Irvine, Irvine, CA, USA., Agulnik M; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Sep 21; Vol. 15, pp. 17588359231199877. Date of Electronic Publication: 2023 Sep 21 (Print Publication: 2023).
DOI:	10.1177/17588359231199877
Abstrakt:	Chondrosarcomas (CSs) consist of a heterogenous group of primary bone cancers arising from malignant cells which produce cartilaginous matrix. As the second most common primary bone cancer, CS are often resistant to systemic chemotherapy due to poor vascularization, slow proliferation, and expression of multidrug-resistant pumps. Immune checkpoint inhibitors have transformed the field of oncology and are now designated as frontline therapy for many solid tumor cancers. Several studies have demonstrated increased expression of programed cell death 1 (PD-1) and PD-L1 in CS tissue in vitro , which has led to the development of multiple clinical trials for immunotherapy in patients with aggressive CS. In this review, we highlight the ongoing investigation into the role for immunotherapy in CS. We also report the case of a 44-year-old female with a history of stage IV primary CS of the right shoulder who underwent radical resection with recurrence and demonstrated a spectacular sustained response to pembrolizumab at our center. Our review highlights the need for further studies investigating the role of immunotherapy in the treatment of aggressive bone sarcomas that are resistant to standard surgical resection, chemotherapy, and radiation treatment. Competing Interests: The authors declare that there is no conflict of interest. (© The Author(s), 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu